Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User

The next-generation breast cancer diagnostic and screening market is evolving rapidly, driven by advances in technology, policy changes, and the growing demand for early detection solutions. Senior executives seeking actionable intelligence will find this report essential for navigating a fragmented, high-growth landscape shaped by constant innovation and competitive shifts.

Market Snapshot: Breast Cancer Diagnostic & Screening Market Overview

The Next-Generation Breast Cancer Diagnostic & Screening Market grew from USD 21.27 billion in 2024 to USD 23.03 billion in 2025. It is expected to continue growing at a CAGR of 8.48%, reaching USD 34.67 billion by 2030. Intensive R&D investment, refined screening programs, and precision molecular profiling underpin this market's expansion. Growth reflects increasing adoption of digital pathology, heightened awareness initiatives, and the integration of advanced imaging modalities into care pathways. Technology developers, clinical laboratories, policy makers, and healthcare providers are reshaping diagnostic standards across diverse global markets.

Scope & Segmentation

Offerings: Digital pathology solutions; imaging technologies (breast ultrasound, MRI, mammography); implantable sensors; liquid biopsy tools; molecular diagnostics (microarrays, next-generation sequencing, PCR-based assays); and wearable devices enabling real-time monitoring.
Test Types: Genetic tests, including BRCA mutation screening and broad genomic profiling; pathological assessments such as cytology and histopathology; and protein marker tests targeting hormone receptors and HER2 status.
Stage: Early stage diagnostic solutions (Stages I and II) and advanced stage monitoring and management (Stages III and IV).
Applications: Early detection initiatives (routine mammograms, self-exams); monitoring of recurrence and treatment response; as well as organized screening programs.
End Users: Academic and research institutes; diagnostic laboratories; hospitals; and specialty clinics addressing tailored patient needs.
Geographic Regions: Americas—including United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, and Argentina; Europe, Middle East & Africa (with countries such as United Kingdom, Germany, France, Russia, Italy, Spain, and others); Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
Key Companies: Abbott Laboratories, Agendia Inc., Agilent Technologies, Becton Dickinson, BGI Genomics, Bio-Rad, Centogene N.V., Danaher Corporation, Epic Sciences, Exact Sciences, F. Hoffmann-La Roche, Fujifilm Holdings, GE HealthCare Technologies, Hologic, Illumina, Invivoscribe, Koninklijke Philips, Laboratory Corporation of America, Merck, Myriad Genetics, Novartis, Oxford Gene Technology, Pfizer, Siemens Healthineers, Thermo Fisher Scientific.

Key Takeaways: Strategic Insights for the Breast Cancer Diagnostic & Screening Market

The integration of artificial intelligence into digital pathology and imaging systems is accelerating diagnostic accuracy and workflow standardization.
Liquid biopsy tools and molecular diagnostics are enabling minimally invasive, real-time tumor profiling, supporting the shift toward more personalized treatment strategies.
Wearable devices and implantable sensors are expanding the scope of patient monitoring, introducing continuous physiological data to supplement traditional clinical visits.
Academic and research institutes play a crucial role in validating disruptive technologies through multicenter trials and driving innovation translation into practice.
Diagnostics adoption in emerging markets is closely tied to public-private partnerships, scalable screening programs, and investments in regulatory harmonization.
Competitive positioning hinges on the ability to deliver interoperable, platform-agnostic solutions that integrate seamlessly into diverse healthcare infrastructures.

Tariff Impact: Adjusting to New Trade Realities

Recent US tariff policies have increased importation costs for diagnostic equipment and materials, prompting suppliers to localize production and optimize supply chains. Onshore partnerships and modular manufacturing approaches are gaining traction, enhancing resilience and mitigating margin pressure. Innovative sourcing, assembly, and cross-border logistics strategies are now critical differentiators for market participants navigating tariff-driven volatility.

Methodology & Data Sources

This analysis is grounded in primary interviews with senior leaders, laboratory directors, clinicians, and regulatory experts, supplemented by peer-reviewed research, regulatory filings, and market intelligence from industry conferences. Segmentation models blend quantitative trade data, financials, and expert qualitative input, ensuring coverage of segment dynamics and regional trends.

Why This Report Matters

Informs strategic planning by highlighting emerging technology, investment priorities, and adoption pathways in breast cancer diagnostics.
Supports resource allocation decisions across R&D, commercialization, and partnership strategies for stakeholders operating globally.

Conclusion

Senior leaders can confidently leverage these insights to adapt to evolving technologies, regulatory environments, and global market demands. Collaboration and a clear grasp of segmentation are vital for sustaining growth and improving patient outcomes in breast cancer diagnostics.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Offerings

8.1. Introduction
8.2. Digital Pathology
8.3. Imaging Technologies
8.3.1. Breast Ultrasound
8.3.2. Magnetic Resonance Imaging
8.3.3. Mammography
8.4. Implantable Sensors
8.5. Liquid Biopsy
8.6. Molecular Diagnostics
8.6.1. Microarrays
8.6.2. Next-Generation Sequencing
8.6.3. PCR-Based Assays
8.7. Wearable Devices

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Test Type

9.1. Introduction
9.2. Genetic Tests
9.2.1. BRCA Testing
9.2.2. Genomic Profiling
9.3. Pathological Tests
9.3.1. Cytology
9.3.2. Histopathology
9.4. Protein Marker Tests
9.4.1. ER/PR Tests
9.4.2. HER2 Tests

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by Stage

10.1. Introduction
10.2. Advanced Stage
10.2.1. Stage III
10.2.2. Stage IV
10.3. Early Stage
10.3.1. Stage I
10.3.2. Stage II

11. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

11.1. Introduction
11.2. Early Detection
11.2.1. Routine Mammograms
11.2.2. Self-Exams
11.3. Monitoring
11.3.1. Recurrence
11.3.2. Treatment Response
11.4. Screening Programs

12. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

12.1. Introduction
12.2. Academic & Research Institutes
12.3. Diagnostic Laboratories
12.4. Hospitals
12.5. Specialty Clinics

13. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina

14. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland

15. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan

16. Competitive Landscape

16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Agendia Inc.
16.3.3. Agilent Technologies, Inc.
16.3.4. Becton, Dickinson and Company
16.3.5. BGI Genomics Co., Ltd.
16.3.6. Bio-Rad Laboratories, Inc.
16.3.7. Centogene N.V.
16.3.8. Danaher Corporation
16.3.9. Epic Sciences, Inc.
16.3.10. Exact Sciences Corporation
16.3.11. F. Hoffmann-La Roche Ltd.
16.3.12. Fujifilm Holdings Corporation
16.3.13. GE HealthCare Technologies, Inc.
16.3.14. Hologic, Inc.
16.3.15. Illumina, Inc.
16.3.16. Invivoscribe, Inc.
16.3.17. Koninklijke Philips N.V.
16.3.18. Laboratory Corporation of America Holdings
16.3.19. Merck & Co., Inc.
16.3.20. Myriad Genetics, Inc.
16.3.21. Novartis AG
16.3.22. Oxford Gene Technology (OGT) Group
16.3.23. Pfizer Inc.
16.3.24. Siemens Healthineers AG
16.3.25. Thermo Fisher Scientific Inc.

17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix

List of Figures

FIGURE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET MULTI-CURRENCY
FIGURE 2. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET MULTI-LANGUAGE
FIGURE 3. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables

TABLE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIGITAL PATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMPLANTABLE SENSORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PCR-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BRCA TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CYTOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HISTOPATHOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ER/PR TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HER2 TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE IV, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ROUTINE MAMMOGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SELF-EXAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RECURRENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TREATMENT RESPONSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 88. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 90. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 91. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 93. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 94. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 95. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 96. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 97. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 98. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 100. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 101. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 104. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 105. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 107. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 109. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 111. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 112. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 114. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 115. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 172. UNITED KINGDOM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 175. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 176. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 178. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 179. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 182. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 183. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 184. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 185. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 186. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 189. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 190. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 191. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 192. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 193. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 194. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 195. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 196. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 197. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 198. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 199. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 200. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 213. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 214. RUSSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 216. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 217. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 218. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 219. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 220. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 221. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 222. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 223. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 224. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 225. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 227. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 228. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 230. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 231. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 232. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 233. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 234. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 235. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 236. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 237. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 238. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
TABLE 239. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY DETECTION, 2018-2030 (USD MILLION)
TABLE 241. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MONITORING, 2018-2030 (USD MILLION)
TABLE 242. SPAIN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PATHOLOGICAL TESTS, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MARKER TESTS, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ADVANCED STAGE, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MIL

Samples

LOADING...

Companies Mentioned

The companies profiled in this Next-Generation Breast Cancer Diagnostic & Screening market report include:

Abbott Laboratories
Agendia Inc.
Agilent Technologies, Inc.
Becton, Dickinson and Company
BGI Genomics Co., Ltd.
Bio-Rad Laboratories, Inc.
Centogene N.V.
Danaher Corporation
Epic Sciences, Inc.
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd.
Fujifilm Holdings Corporation
GE HealthCare Technologies, Inc.
Hologic, Inc.
Illumina, Inc.
Invivoscribe, Inc.
Koninklijke Philips N.V.
Laboratory Corporation of America Holdings
Merck & Co., Inc.
Myriad Genetics, Inc.
Novartis AG
Oxford Gene Technology (OGT) Group
Pfizer Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

Table Information

Report Attribute	Details
No. of Pages	187
Published	May 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 23.03 Billion
Forecasted Market Value ( USD ) by 2030	$ 34.67 Billion
Compound Annual Growth Rate	8.4%
Regions Covered	Global
No. of Companies Mentioned	25

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3112EUR$3,545USD£2,670GBP €3458EUR$3,939USD£2,967GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3357EUR$3,824USD£2,881GBP €3730EUR$4,249USD£3,201GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4550EUR$5,183USD£3,904GBP €5055EUR$5,759USD£4,338GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5506EUR$6,272USD£4,725GBP €6117EUR$6,969USD£5,249GBP

Next-Generation Breast Cancer Diagnostic & Screening Market by Offerings, Test Type, Stage, Application, End User - Global Forecast to 2030

Market Snapshot: Breast Cancer Diagnostic & Screening Market Overview

Scope & Segmentation

Key Takeaways: Strategic Insights for the Breast Cancer Diagnostic & Screening Market